Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?

Overview

Journal J Clin Med

Specialty General Medicine

Date 2018 Jun 13

PMID 29890761

Citations 37

Authors

Simon Garinet

Pierre Laurent-Puig

Helene Blons

Jean-Baptiste Oudart

Affiliations

Soon will be listed here.

Abstract

Recent changes in lung cancer care, including new approvals in first line and the introduction of high-throughput molecular technologies in routine testing led us to question ourselves on how deeper molecular testing may be helpful for the optimal use of targeted drugs. In this article, we review recent results in the scope of personalized medicine in lung cancer. We discuss biomarkers that have a therapeutic predictive value in lung cancer with a focus on recent changes and on the clinical value of large scale sequencing strategies. We review the use of second- and third-generation EGFR and ALK inhibitors with a focus on secondary resistance alterations. We discuss anti-BRAF and anti-MEK combo, emerging biomarkers as NRG1 and NTRKs fusions and immunotherapy. Finally, we discuss the different technical issues of comprehensive molecular profiling and show how large screenings might refine the prediction value of individual markers. Based on a review of recent publications (2012⁻2018), we address promising approaches for the treatment of patients with lung cancers and the technical challenges associated with the identification of new predictive markers.

Citing Articles

Biomarker testing in lung cancer: from bench to bedside.

Batra U, Nathany S Oncol Rev. 2025; 18():1445826.

PMID: 39834530 PMC: 11743711. DOI: 10.3389/or.2024.1445826.

Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer.

Ezzeldin N, El-Lebedy D, Hassan M, Shalaby A, Hussein S, Gharib A J Egypt Natl Canc Inst. 2024; 36(1):21.

PMID: 38880832 DOI: 10.1186/s43046-024-00219-1.

Droplet Digital PCR as a Molecular Tool for the Detection of the T790M Mutation in NSCLC Patients with the Activating Mutations.

Durgut S, Salihefendic L, Pecar D, ceko I, Mulahuseinovic N, Izmirlija M Balkan J Med Genet. 2024; 26(2):21-26.

PMID: 38482255 PMC: 10932593. DOI: 10.2478/bjmg-2023-0020.

Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer.

Zhao Y, Jia S, Zhang K, Zhang L Front Oncol. 2023; 13:1064616.

PMID: 36874133 PMC: 9977806. DOI: 10.3389/fonc.2023.1064616.

Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an Fusion.

Thavaneswaran S, Chan W, Asghari R, Grady J, Deegan M, Jansen V JCO Precis Oncol. 2022; 6:e2200263.

PMID: 36455193 PMC: 9812631. DOI: 10.1200/PO.22.00263.

References

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

Kobayashi Y, Mitsudomi T . Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016; 107(9):1179-86. PMC: 5021039. DOI: 10.1111/cas.12996. View

Peters S, Camidge D, Shaw A, Gadgeel S, Ahn J, Kim D . Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):829-838. DOI: 10.1056/NEJMoa1704795. View

Mambetsariev I, Vora L, Yu K, Salgia R . Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018; 18(1):314. PMC: 5863467. DOI: 10.1186/s12885-018-4222-z. View

Imielinski M, Berger A, Hammerman P, Hernandez B, Pugh T, Hodis E . Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150(6):1107-20. PMC: 3557932. DOI: 10.1016/j.cell.2012.08.029. View

Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg K, Griffin N . FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations. Oncologist. 2018; 23(6):740-745. PMC: 6067947. DOI: 10.1634/theoncologist.2017-0642. View

Tseng C, Chiang C, Tseng J, Yang T, Hsu K, Chen K . EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017; 8(58):98384-98393. PMC: 5716737. DOI: 10.18632/oncotarget.21842. View

Bennett N, Farah C . Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers (Basel). 2014; 6(4):2296-312. PMC: 4276967. DOI: 10.3390/cancers6042296. View

Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K . Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015; 4(2):156-64. PMC: 4384213. DOI: 10.3978/j.issn.2218-6751.2014.11.11. View

10.

Kohsaka S, Nagano M, Ueno T, Suehara Y, Hayashi T, Shimada N . A method of high-throughput functional evaluation of gene variants of unknown significance in cancer. Sci Transl Med. 2017; 9(416). DOI: 10.1126/scitranslmed.aan6566. View

11.

Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles P . A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat Commun. 2018; 9(1):625. PMC: 5809600. DOI: 10.1038/s41467-018-02994-7. View

12.

Provencio M, Torrente M, Calvo V, Perez-Callejo D, Gutierrez L, Franco F . Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. Oncotarget. 2018; 9(1):488-494. PMC: 5787483. DOI: 10.18632/oncotarget.22470. View

13.

Gautschi O, Milia J, Cabarrou B, Bluthgen M, Besse B, Smit E . Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol. 2015; 10(10):1451-7. DOI: 10.1097/JTO.0000000000000625. View

14.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

15.

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

16.

Maroun C, Rowlands T . The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther. 2014; 142(3):316-38. DOI: 10.1016/j.pharmthera.2013.12.014. View

17.

Vaishnavi A, Capelletti M, Le A, Kako S, Butaney M, Ercan D . Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013; 19(11):1469-1472. PMC: 3823836. DOI: 10.1038/nm.3352. View

18.

Koyama S, Akbay E, Li Y, Aref A, Skoulidis F, Herter-Sprie G . STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016; 76(5):999-1008. PMC: 4775354. DOI: 10.1158/0008-5472.CAN-15-1439. View

19.

Van Allen E, Miao D, Schilling B, Shukla S, Blank C, Zimmer L . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-211. PMC: 5054517. DOI: 10.1126/science.aad0095. View

20.

Buzyn A, Blay J, Hoog-Labouret N, Jimenez M, Nowak F, Le Deley M . Equal access to innovative therapies and precision cancer care. Nat Rev Clin Oncol. 2016; 13(6):385-93. DOI: 10.1038/nrclinonc.2016.31. View